SurvivorNet: Perlmutter Cancer Center Medical Oncologist Discusses New Treatment for High-Risk Melanoma
Photo: KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty
The results of a new study show that the immunotherapy pembrolizumab reduces the risk of tumor recurrence in people with high-risk melanoma when used before and after surgery. Janice Mehnert, MD, associate director of clinical research at TV Langone Health’s Perlmutter Cancer Center, talks with SurvivorNet about the study and what it means for people with high-risk melanoma.
“It’s important that patients and physicians are aware of this study as it represents a new potential standard of care,” says Dr. Mehnert, also a professor in the at TV Grossman School of Medicine. “For patients with high-risk disease, delivering immunotherapy before surgery must be considered.”
Read more from .
